Nootropic Peptide

Selank

Russian-developed anxiolytic peptide with limited Western clinical validation.

GABA-A receptor modulationIL-6/inflammatory cytokinesEnkephalin degradationBDNF expression

34 D+

Evidence Score

ⓘ For informational purposes only — not medical advice.

Score Breakdown

Overview

Selank is a synthetic peptide analog of the naturally occurring immunomodulatory peptide tuftsin, developed at the Institute of Molecular Genetics in Moscow. It is approved in Russia as an anxiolytic and nootropic. Selank is proposed to modulate both the immune system and central nervous system, with reported anxiolytic effects comparable to benzodiazepines without sedation or dependence.

Mechanism of Action

Selank is proposed to enhance GABAergic neurotransmission, stabilize enkephalins (endogenous opioid peptides) by inhibiting their enzymatic degradation, and modulate pro-inflammatory cytokine expression (IL-6, TNF-α). The dual immunomodulatory and anxiolytic mechanism makes it unique among peptide nootropics.

Evidence Base

Approved in Russia for generalized anxiety disorder and as an immunomodulator. Published studies are primarily in Russian-language journals. A few English-language publications describe anxiolytic and immunomodulatory effects in animal models. No Western peer-reviewed RCTs or FDA evaluation.

Gene Pathway Detail

Selank modulates GABA receptor subunit expression, influences IL-6 and TNF-α cytokine gene expression, and may upregulate BDNF through indirect pathways. The immunomodulatory targets (cytokine genes) are more amenable to peripheral blood transcriptomic monitoring than the CNS targets.

mRNA Monitoring Insight

Cytokine gene expression (IL-6, TNF-α) is readily monitorable in peripheral blood and may provide the most accessible transcriptomic readout for Selank. BDNF and GABA-related targets are more challenging to assess peripherally.

Safety Considerations

Approved for clinical use in Russia, suggesting evaluated safety in that regulatory context. Administered intranasally. No reported dependence or withdrawal effects, unlike benzodiazepines. No Western regulatory evaluation or long-term safety data.

FAQ

How does Selank compare to Semax?

Both are Russian-developed intranasal peptides, but they target different pathways. Semax is primarily nootropic/neuroprotective (BDNF/ACTH pathways), while Selank is primarily anxiolytic/immunomodulatory (GABA/cytokine pathways). They are sometimes stacked together.

Quick Facts

Category: Nootropic Peptide
Score: 34/100 (D+)
Gene Pathways: 4 characterized

Sources

[1] Selank Anxiolytic Activity — Bull Exp Biol Med 2008

Compare Others

Monitor Your Peptide Response.

Biomeme's transcriptomic platform tracks molecular pathway engagement so you know if your therapy is working.